Evommune, a biotechnology firm based in California, has secured $115 million in Series C funding to advance its treatments for chronic immune conditions.
Evommune's lead candidate, EVO756, is a small molecule being tested for chronic skin hives. The company's approach involves an oral medication that blocks a specific protein on mast cells, potentially offering a more effective alternative to traditional treatments.
Other pharmaceutical companies, including Celldex Therapeutics, Novartis, and Sanofi and Regeneron, are also exploring new therapies for urticaria. Evommune's unique oral delivery method could provide advantages in terms of patient compliance and convenience.
Evommune is also developing a second drug, EVO301, which targets a different inflammatory cytokine.
This funding will support three Phase 2 clinical trials, with results expected by the end of 2026. The recent funding round, co-led by RA Capital Management and Sectoral Asset Management, reflects the growing interest in effective treatments for chronic immune conditions.
The CEO of Evommune, Luis Pena, is confident in EVO756's potential and the company plans to present more comprehensive findings at an upcoming conference. Evommune's leadership team is optimistic about the company's future and is considering various strategic options, including a potential IPO.
As the company moves forward, it will be important to monitor the outcomes of its clinical trials and the competitive landscape.